Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index

Jie Shi  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Zixuan Wang  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Weiwei Zhang  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Yixin Niu  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Ning Lin  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Xiaoyong Li  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Hongmei Zhang  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Guang Ning  
Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Jiangao Fan  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Li Qin  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Qing Su  
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Zhen Yang  
Shanghai Jiaotong University School of Medicine Xinhua Hospital  
https://orcid.org/0000-0003-0225-7099

Research

Keywords: neck circumference, nonalcoholic fatty liver disease, postmenopausal women, normal body mass index
Abstract

Background

Neck circumference, a proxy for upper-body subcutaneous fat, is a unique and pathogenic fat depot that confers additional metabolic risk. The purpose of present study was to determine whether neck circumference associates with nonalcoholic fatty liver disease (NAFLD) in postmenopausal women with normal body mass index.

Methods

A cross-sectional survey (n = 2492) and a 3.1-year follow-up investigation (n = 1354) were conducted among Chinese postmenopausal women with normal BMI (18.5 to < 25 kg/m²). Neck circumference was measured horizontally at the lower margin of the laryngeal prominence.

Results

In the cross-sectional analysis, large neck circumference was associated with the presence of NAFLD (odds ratio 2.28; 95% CI 1.74–2.98; highest tertile versus lowest tertile) after adjustment for confounding factors. Among 1,354 subjects without the NAFLD at baseline, 429 (31.7%) incident NAFLD cases occurred at 3.1 years. Neck circumference was positively associated with triglycerides, homeostasis model assessment of insulin resistance, C-reactive protein, and negatively associated with high-density lipoprotein cholesterol and adiponectin. Individuals with large baseline neck circumference had a significantly higher risk of NAFLD than those with small neck circumference. The multivariable adjusted hazard ratio was 1.42 (95% CI 1.15–1.97; p for trend = 0.004) for the highest versus the lowest tertile of neck circumference, and was 1.22 (95% CI 1.10–1.41; p = 0.006) per 1-standard deviation increment in neck circumference.

Conclusions

Among postmenopausal women with normal BMI, relatively large neck circumference levels are associated with an increased risk of NAFLD.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver with the absence of alcohol and other liver diseases. It is well established that adiposity is a major contributor to NAFLD. Data from epidemiological studies revealed that NAFLD occurrence in up to 70% of overweight adults worldwide [1] and in 90% of morbidly obese adults globally [2]. Nonetheless, a remarkable proportion of individuals having NAFLD with a relatively normal body mass index (BMI), a condition
termed as “non-obese” NAFLD. The prevalence of NAFLD was around 10% in nonobese adults in Western countries, and about 8–19% of Asians with BMI less than 25 kg/m² are also found to have NAFLD [3]. Given this trend, a reliable predictor of NAFLD in nonobese people is essential for its prevention and management.

As we best known, the larger the BMI, the higher the metabolic risk. However, individuals within the same BMI status could have considerable differences in the amount and distribution of regional fat depot, leading to variable metabolic risks [4, 5]. Numerous researches highlight the metabolic risk conferred by specific patterns of fat distribution, particularly upper body adiposity [6]. Notably, several studies have recently shown that upper-body subcutaneous adipose tissue, estimated by neck circumference, is a unique fat depot that confer additional metabolic risks beyond generalized and abdominal adiposity [7, 8]. It is reported that neck circumference levels are significantly associated with hyperlipidemia, impaired glucose homeostasis, and insulin resistance, especially in women [7]. All of these supported the investigation of a possible association of neck circumference with NAFLD.

Due, in part, to a transfer from subcutaneous to abdominal visceral fat, women after menopause are prone to metabolic changes [9]. Such metabolic alterations are associated with increased NAFLD risk among normal BMI populations. However, studies that assess neck fat accumulation, as a proxy for upper-body subcutaneous fat, and its relationship with NAFLD among postmenopausal women with normal BMI are still lacking. In the current study, we evaluated the relationship between neck circumference and NAFLD among postmenopausal women with normal BMI.

**Patients And Methods**

**Study subjects**

Participants were recruited from the China Cardiometabolic Disease and Cancer Cohort (4C) Study, a nationwide prospective cohort study investigating the associations of metabolic factors with specific clinical outcomes, including diabetes, cardiovascular disease, cancer, and all-cause mortality [10, 11]. The data presented in this study are based on the subsamples from the Chongming District in Shanghai, China. From May to November 2011, a total of 2,765 postmenopausal women with normal BMI of Chinese origins were enrolled in the study. From June to December 2014, the subjects were invited for follow-up assessments. The cross-sectional survey included 2,492 subjects, and the follow-up investigation included 1,354 individuals without NAFLD at baseline (Figure 1). Subjects with the following conditions were excluded from this study: virus hepatitis, autoimmune hepatitis, drug-induced liver disease, current drinkers, ex-drinkers, presence of tumor, biliary obstructive diseases, thyroid dysfunction, total parenteral nutrition, Wilson's disease, severe renal insufficiency, significant hematologic disorders, and current treatment with systemic corticosteroids.

The study protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all participants.
Clinical diagnosis of NAFLD

Guidelines for the diagnosis of NAFLD proposed by the Asia-Pacific Working Party were used [12]. NAFLD was clinically defined as manifestations of B-mode ultrasonography, after the exclusion of the habit of drinking and the history of specific diseases that could lead to fatty liver. Abdominal ultrasonography was performed by experienced ultrasonographers who were blinded to clinical presentation and laboratory data. Hepatic steatosis was defined as a diffuse increase of fine echoes in the liver parenchyma compared with that in the kidney or spleen parenchyma based on standard criteria.

Anthropometric and biochemical measurements

Neck circumference was measured horizontally at the lower margin of the laryngeal prominence (Adam’s apple), with head erect and eyes facing forward. BMI was calculated as the weight in kilograms divided by the square of the height in meters. Waist circumference was measured at the midpoint between the inferior costal margin and the superior border of the iliac crest on the midaxillary line.

Serum total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, triglycerides, alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltranspeptidase were measured on an autoanalyzer (Hitachi 7080; Tokyo, Japan). Venous plasma glucose level was determined by glucose oxidase method (ADVIA-1650 Chemistry System, Bayer, Leverkusen, Germany) and hemoglobin A1c was measured by high-performance liquid chromatography (BIO-RAD, D10, CA). Fasting insulin was measured by RIA (Linco Research, St. Charles, MO). The homeostasis model assessment-insulin resistance (HOMA-IR) was used to assess insulin resistance, which was calculated using the following equation: HOMA-IR = insulin (uU/mL) * glucose (mmol/L)/22.5 [13]. Serum C-reactive protein (CRP) and adiponectin levels were quantified using the enzyme-linked immunosorbent assay (ELISA) kits (DY1707, DY1065; R&D Systems, Minneapolis, MN).

Statistical analysis

The continuous variables with normal distribution are expressed as means ± SDs. The continuous variables with skewed distribution are shown as medians (interquartile range) and log-transformed to approximate normality before analysis. Categorical variables are reported as frequencies (%). For comparisons between groups, we conducted an independent-samples Student t test for normally distributed variables and a Mann-Whitney U test for variables with highly skewed distributions. The Chi-squared test was performed to compare categorical variables. The correlation coefficients between neck circumference and metabolic parameters were calculated using the Pearson correlation analysis. Multivariate Cox regression analyses were run to evaluate the potential association between neck circumference and the incidence of NAFLD. We also used restricted cubic splines with five knots at percentiles 5%, 35%, 50%, 65%, and 95% of the distribution to flexibly model to assess the association of neck circumference on a continuous scale and the incidence of NAFLD. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationship between neck circumference and the incidence of NAFLD were generated with the Cox regression models.
A 2-tailed \( p < 0.05 \) was considered statistically significant. All analyses were performed using R version 4.0.2 and SPSS software version 25.0.

**Results**

**Association between neck circumference and the presence of NAFLD in the cross-sectional survey**

The clinical characteristics of the study subjects are shown in Table 1. Neck circumference was larger in individuals with NAFLD than those without NAFLD (33.4 ± 2.6 cm vs. 32.0 ± 2.4 cm, \( p < 0.001 \)). When stratified by tertiles of neck circumference, the prevalence of NAFLD raised sharply from the lowest tertile to the highest tertile group (15.9%, 29.7%, 47.5%, respectively). According to logistic regression analyses, large neck circumference was associated with the presence of NAFLD (odds ratio, 2.28; 95% CI, 1.74-2.98; highest versus lowest tertile, \( p < 0.001 \)) after adjustment for age, smoking status, physical activity, educational attainment, BMI, waist circumference, HOMA-IR, CRP, adiponectin, fasting plasma glucose, post-loading plasma glucose, systolic blood pressure, diastolic blood pressure, lipid profiles, and liver enzymes (Table 2).

**Association between baseline neck circumference and the incidence of NAFLD in the follow-up investigation**

During a 3.1-year follow-up period, 429 participants developed NAFLD. The clinical characteristics of the study subjects are presented in Table 3. According to Pearson correlations analyses, the neck circumference was positively correlated with BMI, waist circumference, triglycerides, HOMA-IR, and CRP. In contrast, neck circumference was negatively correlated with HDL-C and adiponectin (Table 4).

We used Cox regression analysis with the lowest neck circumference tertile group as a reference to assess the relationship between neck circumference and the risk of incident NAFLD. As presented in Table 5, the HRs for incident NAFLD was higher with increasing neck circumference tertiles. In the highest neck circumference tertile, the HR was 2.16 (95% CI 1.60-2.92; \( p \) for trend <0.001) for incident NAFLD after adjusting for age, smoking, physical activity, and educational attainment (model 1). Interestingly, further adjustment for BMI and waist circumference (model 2) only slightly reduced the magnitude of the HRs for incident NAFLD. Furthermore, there were still statistically significant (HR 1.42; 95% CI 1.15-1.97; \( p \) for trend =0.004) by additional adjustment for HOMA-IR, CRP, adiponectin, glucose parameters, systolic blood pressure, diastolic blood pressure, lipid profiles, and liver enzymes (model 5). When neck circumference was considered as a continuous variable, the overall HR (95% CI) of having NAFLD was 1.22 (1.10-1.41) per 1-SD increment of neck circumference. A positive linear circumference-response relationship was evident in the cubic spline regression model (Figure 2, \( p \) for nonlinearity >0.1).

Considering the contribution of general obesity, abdominal obesity, and insulin resistance to the development of NAFLD, we further evaluated the combined effect of neck circumference with BMI, waist circumference, and HOMA-IR on fatty liver, respectively. The positive association between neck circumference and risk of incident NAFLD remained consistent across a wide range of BMI, waist...
circumference, and HOMA-IR (Figure 3). And subjects with larger neck circumference combine with higher BMI, waist circumference, or HOMA-IR have a substantially increased incidence of NAFLD.

Subgroup analyses

Subgroup analyses were performed to examine potential effect modifiers, stratified by age (<65 years versus ≥65 years), BMI (<23 kg/m² versus ≥23 kg/m²), waist circumference (<80 cm versus ≥80 cm), CRP (<3.0 mg/L versus ≥3.0 mg/L), diabetes status (No versus Yes), and physical activity (low versus moderate versus high). In the stratified analyses, the positive associations between neck circumference and the risk of incident NAFLD remained consistent across all subgroups (Figure 4). No interaction was observed with any of the variables (all p for interaction >0.1).

Discussion

In the present study, we observed that relatively large neck circumference was associated with the prevalence and incidence of NAFLD among postmenopausal women with normal BMI. Higher neck fat accumulation was also associated with metabolic dysregulation and inflammation characterized by insulin resistance, elevated triglycerides, and CRP. Collectively, these findings indicate the importance of excessive neck fat accumulation to predict the development of NAFLD among postmenopausal women with normal BMI.

Epidemiological studies have shown that sex and menopause affect the prevalence and incidence of NAFLD [14]. In women, the relations between visceral fat accumulation and metabolic profile were greater than in men [15]. Furthermore, as age increases and estrogen levels decrease, women after menopause are prone to insulin resistance, hyperlipidemia, and visceral fat accumulation [16, 17], all of which are known risk factors for NAFLD. The robust protective role of estrogens was revealed in epidemiological studies, where the prevalence of NAFLD is lower in premenopausal women compared to men or postmenopausal women [18]. As the main circulating estrogen, 17β-estradiol has effects beyond reproductive health. In insulin-sensitive tissues like skeletal muscle, 17β-estradiol receptor α has a positive effect on insulin signaling and glucose transporter-4 expression [19], which indicates that 17β-estradiol may directly regulate insulin action. Meanwhile, another study showed that exposure to 17β-estradiol restores insulin sensitivity and glucose tolerance in high fat diet-fed ovariectomized mice [20]. In addition to insulin sensitivity, estrogens can also affect adipose tissue metabolism, energy expenditure, and hepatic glucogenesis [21]. Collectively, the protective effect of estrogen on NAFLD is a combination of multiple factors and its underlying mechanism remains to be further studied.

Previous researches reported that higher BMI, waist circumference, HOMA-IR, elevated triglyceride levels, and reduced HDL-cholesterol levels were associated with NAFLD among non-obese individuals [22]. In our study, neck circumference was significantly correlated with BMI, waist circumference, HOMA-IR, and triglycerides, and negatively correlated with HDL-C, consistent with previous studies [7, 23]. Moreover, the positive association between neck circumference and incidence of NAFLD remained consistent across a
wide range of BMI, waist circumference, and HOMA-IR among postmenopausal women with normal weight. Additionally, previous cross-sectional studies have shown that neck circumference was an independent predictor for NAFLD in the general population [24] and non-obese men [25]. Our strong evidence indicating the relation of neck circumference and incidence of NAFLD even in postmenopausal women with normal BMI may validate their results and provide valuable clues for further studies.

It is well established that obesity is a heterogeneous disorder. BMI is a common screening measure to identify subjects with abnormal body fat distribution. However, BMI cannot provide accurate information about the regional distribution of body fat. Moreover, subjects within the same BMI could have considerable differences in the amount and distribution of regional fat accumulation. Previous studies have demonstrated that differences in body fat distribution result in specific metabolic complications [26, 27]. Thus, neck circumference, a proxy of neck subcutaneous fat, began to show diagnostic value for evaluating metabolic disturbances.

As an alternative measurement of upper-body subcutaneous fat, neck circumference is a great indicator of ectopic fat distribution. Subcutaneous fat in the upper body accounts for a much greater proportion of systemic free fatty acids release and is more lipolytically active than lower body adipose tissue [7]. Large neck circumference means excessive accumulation of subcutaneous fat in neck, which contributes a greater flux of the free fatty acid released into the circulation. Subsequently, elevated free fatty acid contributes to increased synthesis and ectopic deposition of triglycerides, insulin resistance, and inflammation [28]. In addition, increased free fatty acids involved in impaired glucose homeostasis by inhibiting glucose uptake, oxidation, glycogen synthesis, and increasing output hepatic glucose [29]. Concomitantly, excessive free fatty acids could trigger oxidative stress, an early instigator of NAFLD [30], and endoplasmic reticulum stress which intersects with various inflammatory and stress signaling pathways through unfolded protein response [31]. The excessive free fatty acids release derived from neck subcutaneous adipose might be a potential link between neck circumference and NAFLD.

In our study, neck circumference was positively correlated with C-reactive protein, and negatively correlated with adiponectin. As we best known, the abnormal accumulation of fat is associated with adipose tissue metabolic capacities, endocrine, and immune function, which along with altered lipid mediators, adipokines, pro- or anti-inflammatory cytokines, and impaired signaling pathways that involved in metabolic abnormalities [32]. In addition to being a depot of fat, the adipose tissue is also a highly active endocrine organ, secreting various biologically active molecules, collectively termed adipokines [33]. When adipose tissue expands, the capacity of adipocytes to act as endocrine cells and secrete a variety of adipokines is altered in subjects with NAFLD [34]. These altered kinds and levels of adipokine are associated with dysregulation of triglyceride, fatty acids metabolism, and insulin resistance [35]. Moreover, due to excessive fat accumulation and substantial infiltration of immune cells, a specific crown-like disposition of macrophages around single necrotic adipocytes occurs in subjects with NAFLD [36]. Subsequently, proinflammatory pathways were activated, and a variety of proinflammatory cytokines and chemokines were overflowed that contribute to low-grade inflammation and insulin
resistance [32]. In general, adipose dysfunctions, inflammation, and stress partly linking neck obesity to insulin resistance and NAFLD.

Several potential limitations of the current study should also be noted. First, we did not quantify the tissue composition of the neck. The use of neck circumference to assess the neck subcutaneous fat was a convenient and practical way but was unable to quantify the fat accumulation and muscle mass. Hence, the amount and size of subcutaneous adipocyte and muscle fat are unclear. Second, due to ultrasonographic examination was performed to determine the presence of NAFLD, the sensitivity of liver ultrasonography may vary depending on the hepatic fat content. Nevertheless, when performed properly, ultrasonography has been reported to detect as little as ≥ 5% hepatic fat content. Although as discussed above, liver ultrasonography offers several strengths including the non-invasive nature of the test, portability, low cost, and simplicity of use, make it further applicable and acceptable in large-scale epidemiological studies, particularly in developing countries. Third, given the diagnosis of NAFLD was based on ultrasound imaging, NAFLD patients in our study were in at least a moderate stage of the disease. Therefore, in the present study, we were unable to determine the relationship between neck circumference and mild-stage NAFLD.

Conclusions

Large neck circumference was significantly associated with an increased risk of NAFLD among postmenopausal women with normal BMI. Measurement of neck circumference may provide a more complete understanding of NAFLD risk associated with variation in fat distribution among postmenopausal women with normal BMI.

Abbreviations

ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GGT, γ-glutamyltransferase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease; PPG, postprandial plasma glucose; SBP, systolic blood pressure; WC, waist circumference.

Declarations

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all participants before data collection.

Consent for publication
Not applicable.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Competing interests

No potential conflicts of interest relevant to this article were reported.

Funding

This work was supported by the National Natural Science Foundation of China (81970669, 81873565, 81670743, 81370953), the National Key Research and Development Plan ‘Precision Medicine Research’ (2017YFSF090203), the Shanghai Health System Outstanding Young Talents Training Program (XYQ2013098), the Shanghai Sailing Program (18YF1415800), the Shanghai Health and Family Planning Commission (21740173).

Authors’ contributions

JS, ZW, and WZ drafted the manuscript and performed the experiments. ZY, JF, QS, LQ, and GN conceived and designed the study. WZ, YN, XL, HZ, and NL recruited the subjects, processed samples, and contributed to the acquisition of data. JS and ZY analyzed the data. ZY revised the manuscript.

Acknowledgements

The authors gratefully acknowledge the support of the study participants, study staff, and partner organizations participating in the baseline survey and follow-up investigation.

References

1. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of internal medicine 2000, 132:112-117.

2. Silverman JF, O’Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, Caro JF: Liver pathology in morbidly obese patients with and without diabetes. The American journal of gastroenterology 1990, 85:1349-1355.

3. Fan J-G, Kim S-U, Wong VW-S: New trends on obesity and NAFLD in Asia. Journal of hepatology 2017, 67:862-873.

4. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL: Mechanisms and metabolic implications of regional differences among fat depots. Cell metabolism 2013, 17:644-656.
5. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F: Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. European heart journal 2010, 31:737-746.

6. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD: Splanchnic lipolysis in human obesity. The Journal of clinical investigation 2004, 113:1582-1588.

7. Preis SR, Massaro JM, Hoffmann U, D'Agostino RB, Levy D, Robins SJ, Meigs JB, Vasan RS, O'Donnell CJ, Fox CS: Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. The Journal of clinical endocrinology and metabolism 2010, 95:3701-3710.

8. Zhou JY, Ge H, Zhu MF, Wang LJ, Chen L, Tan YZ, Chen YM, Zhu HL: Neck circumference as an independent predictive contributor to cardio-metabolic syndrome. Cardiovasc Diabetol 2013, 12:76.

9. JafariNasabian P, Inglis JE, Reilly W, Kelly OJ, Ilich JZ: Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake. The Journal of endocrinology 2017, 234:R37-R51.

10. Lu J, He J, Li M, Tang X, Hu R, Shi L, Su Q, Peng K, Xu M, Xu Y, et al: Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A on Risk of Diabetes and Complications in Chinese Adults. Diabetes care 2019, 42:1539-1548.

11. Wang T, Lu J, Su Q, Chen Y, Bi Y, Mu Y, Chen L, Hu R, Tang X, Yu X, et al: Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes. JAMA cardiology 2019, 4:874-883.

12. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GKK, Sollano JD: Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Journal of gastroenterology and hepatology 2007, 22:778-787.

13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.

14. Suzuki A, Abdelmalek MF: Nonalcoholic fatty liver disease in women. Women's health (London, England) 2009, 5:191-203.

15. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al: Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39-48.

16. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR: Increased visceral fat and decreased energy expenditure during the menopausal transition. International journal of obesity (2005) 2008, 32:949-958.

17. Gupte AA, Pownall HJ, Hamilton DJ: Estrogen: an emerging regulator of insulin action and mitochondrial function. Journal of diabetes research 2015, 2015:916585.

18. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
19. Barros RP, Gabbi C, Morani A, Warner M, Gustafsson JA: Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. *Am J Physiol Endocrinol Metab* 2009, **297:**E124-133.

20. Riant E, Waget A, Cogo H, Amal JF, Burcelin R, Gourdy P: Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. *Endocrinology* 2009, **150:**2109-2117.

21. Gupte AA, Pownall HJ, Hamilton DJ: Estrogen: an emerging regulator of insulin action and mitochondrial function. *J Diabetes Res* 2015, **2015:**916585.

22. Wei JL, Leung JC-F, Loong TC-W, Wong GL-H, Yeung DK-W, Chan RS-M, Chan HL-Y, Chim AM-L, Woo J, Chu WC-W, Wong VW-S: Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. *The American journal of gastroenterology* 2015, **110**.

23. Liang J, Teng F, Li Y, Liu X, Zou C, Wang Y, Li H, Qi L: neck circumference and insulin resistance in Chinese adults: the Cardiometabolic Risk in Chinese (CRC) Study. *Diabetes Care* 2013, **36:**e145-146.

24. Huang B-x, Zhu M-f, Wu T, Zhou J-y, Liu Y, Chen X-I, Zhou R-f, Wang L-J, Chen Y-m, Zhu H-I: Neck circumference, along with other anthropometric indices, has an independent and additional contribution in predicting fatty liver disease. *PloS one* 2015, **10:**e0118071.

25. Li Q, Wang N, Han B, Chen Y, Zhu C, Chen Y, Xia F, Cang Z, Zhu C, Chen C, et al: Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men. *Nutrition & metabolism* 2015, **12:**63.

26. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM: Influence of body fat distribution on free fatty acid metabolism in obesity. *The Journal of clinical investigation* 1989, **83:**1168-1173.

27. Jensen MD: Role of body fat distribution and the metabolic complications of obesity. *The Journal of clinical endocrinology and metabolism* 2008, **93:**S57-S63.

28. Hotamisligil GS: Inflammation, metaflammation and immunometabolic disorders. *Nature* 2017, **542:**177-185.

29. Bergman RN, Ader M: Free fatty acids and pathogenesis of type 2 diabetes mellitus. *Trends in endocrinology and metabolism: TEM* 2000, **11:**351-356.

30. Byrne CD, Targher G: NAFLD: a multisystem disease. *Journal of hepatology* 2015, **62:**S47-S64.

31. Hotamisligil GS: Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 2010, **140:**900-917.

32. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. *The Journal of clinical investigation* 2003, **112:**1796-1808.

33. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. *The Journal of clinical endocrinology and metabolism* 2004, **89:**2548-2556.

34. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic
syndrome. *The Journal of clinical investigation* 2004, 114:1752-1761.

35. Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nature reviews Molecular cell biology* 2008, 9:367-377.

36. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot J-L, et al: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* 2005, 54:2277-2286.

Tables

Table 1. Characteristics of subjects according to the presence or absence of the nonalcoholic fatty liver diseases at baseline
| Variables                 | Non-NAFLD (n = 1,724) | NAFLD (n = 768) | p value |
|---------------------------|------------------------|-----------------|---------|
| Age (years)               | 58.7 ± 5.6             | 58.8 ± 5.3      | 0.62    |
| BMI (kg/m²)               | 22.22 ± 1.61           | 23.27 ± 1.40    | <0.001  |
| Waist circumference (cm)  | 78.2 ± 7.1             | 82.6 ± 6.6      | <0.001  |
| SBP (mmHg)                | 127.77 ± 18.13         | 131.27 ± 18.57  | <0.001  |
| DBP (mmHg)                | 77.15 ± 9.73           | 79.47 ± 9.66    | <0.001  |
| FPG (mmol/L)              | 6.00 ± 1.36            | 6.68 ± 2.06     | <0.001  |
| PPG (mmol/L)              | 7.96 ± 3.25            | 9.87 ± 4.47     | <0.001  |
| HbA₁c (%)                 | 5.90 ± 0.84            | 6.30 ± 1.22     | <0.001  |
| HOMA-IR                   | 1.49 (1.16-1.93)       | 2.29 (1.65-2.97)| <0.001  |
| HDL-C (mmol/L)            | 1.33 ± 0.32            | 1.19 ± 0.30     | <0.001  |
| LDL-C (mmol/L)            | 2.67 ± 0.76            | 2.71 ± 0.82     | 0.174   |
| Total cholesterol (mmol/L)| 4.74 ± 1.00            | 4.86 ± 1.06     | 0.011   |
| Triglycerides (mmol/L)    | 1.18 (0.89-1.60)       | 1.71 (1.21-2.50)| <0.001  |
| ALT (U/L)                 | 12 (9-16)              | 15 (11-23)      | <0.001  |
| AST (U/L)                 | 18 (15-22)             | 19 (16-24)      | 0.004   |
| GGT (U/L)                 | 15 (11-20)             | 20 (14-31)      | <0.001  |
| CRP (mg/L)                | 1.09 (0.58-2.01)       | 2.04 (1.10-3.16)| <0.001  |
| Adiponectin (mg/L)        | 3.81 ± 1.17            | 3.19 ± 0.97     | <0.001  |
| Neck circumference (cm)   | 32.0 ± 2.4             | 33.4 ± 2.6      | <0.001  |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GGT, γ-Glutamyltransferase; HbA₁c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; PPG, postprandial plasma glucose; SBP, systolic blood pressure.

**Table 2. Presence of nonalcoholic fatty liver diseases in relation to neck circumference tertiles (n = 2,492)**
| Neck circumference | Tertile 1 (n = 830) | Tertile 2 (n = 831) | Tertile 3 (n = 831) | p for trend |
|---------------------|---------------------|---------------------|---------------------|------------|
| Prevalence of NAFLD (%) | 132 (15.9) | 247 (29.7) | 395 (47.5) | <0.001 |
| Model 1 OR (95% CI) | 1.00 | 2.24 (1.77-2.84) | 4.79 (3.80-6.04) | <0.001 |
| Model 2 OR (95% CI) | 1.00 | 1.80 (1.41-2.30) | 3.52 (2.76-4.48) | <0.001 |
| Model 3 OR (95% CI) | 1.00 | 1.70 (1.33-2.18) | 3.05 (2.38-3.92) | <0.001 |
| Model 4 OR (95% CI) | 1.00 | 1.64 (1.28-2.10) | 2.84 (2.21-3.65) | <0.001 |
| Model 5 OR (95% CI) | 1.00 | 1.42 (1.09-1.85) | 2.28 (1.74-2.98) | <0.001 |

Model 1 was adjusted for age, smoking status, physical activity, and educational attainment. Model 2 was further adjusted for BMI and waist circumference. Model 3 was further adjusted for HOMA-IR, CRP, and adiponectin. Model 4 was further adjusted for model 3 variables and fasting glucose, post-loading plasma glucose, systolic blood pressure, diastolic blood pressure. Model 5 was further adjusted for lipid profiles and liver enzymes.

Table 3. Baseline characteristics of subjects with or without development of nonalcoholic fatty liver diseases at 3.1 years.
| Variables                        | Non-NAFLD (n = 925) | NAFLD (n = 429) | p value |
|---------------------------------|---------------------|-----------------|---------|
| Age (years)                     | 58.6 ± 5.7          | 58.7 ± 5.5      | 0.678   |
| BMI (kg/m^2)                    | 21.95 ± 1.61        | 22.79 ± 1.48    | <0.001  |
| Waist circumference (cm)        | 77.3 ± 6.7          | 80.5 ± 6.1      | <0.001  |
| SBP (mmHg)                      | 126.91 ± 17.89      | 129.38 ± 18.29  | 0.023   |
| DBP (mmHg)                      | 76.95 ± 9.66        | 78.21 ± 9.70    | 0.031   |
| FPG (mmol/L)                    | 5.88 ± 1.20         | 6.20 ± 1.55     | <0.001  |
| PPG (mmol/L)                    | 7.61 ± 2.95         | 8.48 ± 3.45     | <0.001  |
| HbA1c (%)                       | 5.84 ± 0.71         | 5.93 ± 0.96     | 0.104   |
| HOMA-IR                         | 1.36 (1.00-1.79)    | 1.72 (1.36-2.41)| <0.001  |
| HDL-C (mmol/L)                  | 1.36 ± 0.34         | 1.28 ± 0.31     | <0.001  |
| LDL-C (mmol/L)                  | 2.67 ± 0.77         | 2.70 ± 0.76     | 0.552   |
| Total cholesterol (mmol/L)      | 4.75 ± 1.03         | 4.80 ± 1.00     | 0.464   |
| Triglycerides (mmol/L)          | 1.14 (0.86-1.51)    | 1.40 (0.99-1.96)| <0.001  |
| ALT (U/L)                       | 11 (8-15)           | 13 (10-16)      | <0.001  |
| AST (U/L)                       | 19 (15-23)          | 19 (15-22)      | 0.781   |
| GGT (U/L)                       | 14 (11-19)          | 16 (12-23)      | <0.001  |
| CRP (mg/L)                      | 1.04 (0.57-1.95)    | 1.28 (0.68-2.40)| <0.001  |
| Adiponectin (mg/L)              | 3.98 ± 1.16         | 3.46 ± 1.13     | <0.001  |
| Neck circumference (cm)         | 31.6 ± 2.2          | 32.4 ± 2.2      | <0.001  |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GGT, γ-Glutamyltransferase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol; PPG, postprandial plasma glucose; SBP, systolic blood pressure.

**Table 4. Pearson correlations of baseline neck circumference with metabolic characteristics**
| Variables            | r    | p value   |
|----------------------|------|-----------|
| Body mass index      | 0.230| < 0.001   |
| Waist circumference  | 0.313| < 0.001   |
| HDL-C                | -0.144| < 0.001  |
| Triglycerides        | 0.104| < 0.001   |
| HOMA-IR              | 0.128| < 0.001   |
| CRP                  | 0.103| 0.002     |
| Adiponectin          | -0.110| < 0.001  |

Abbreviations: CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance.

Table 5. Incidence of NAFLD in relation to neck circumference (n = 1,354)

| NAFLD        | highest tertile vs. lowest tertile | per 1 SD, as continuous variable |
|--------------|-----------------------------------|----------------------------------|
| Reference    | HR (95% CI)                       | p for trend                      |
| Model 1      | 1.00 2.16 (1.60-2.92)             | < 0.001                          |
| Model 2      | 1.00 1.79 (1.31-2.46)             | < 0.001                          |
| Model 3      | 1.00 1.66 (1.21-2.27)             | < 0.001                          |
| Model 4      | 1.00 1.51 (1.17-2.09)             | 0.001                            |
| Model 5      | 1.00 1.42 (1.15-1.97)             | 0.004                            |

Model 1 was adjusted for age, smoking status, physical activity, and educational attainment. Model 2 was further adjusted for BMI and waist circumference. Model 3 was further adjusted for HOMA-IR, CRP, and adiponectin. Model 4 was further adjusted for model 3 variables and fasting glucose, post-loading plasma glucose, systolic blood pressure, diastolic blood pressure. Model 5 was further adjusted for lipid profiles and liver enzymes.